Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 5/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88684 | 1.00 | FKBP1A (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL2737884 | 1.00 | FKBP1A (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL2738084 | 0.98 | FKBP1A (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL18455416 | 0.98 | FKBP1A (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL883030 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL1486184 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL190042 | 0.95 | HSD17B10 (0.58) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| Hydrochloric Acid SCHEMBL29889454 | 0.94 | HSD17B10 (0.57) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL927348 | 0.90 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA | |
| SCHEMBL28153746 | 0.90 | HSD17B10 (0.56) | FKBP1AHSD17B10SMN1; SMN2NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119923395-A | N-heterocyclic GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods of use thereof | 卡莫特医疗有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-03-20 | — | — | US | disclosed |
| US-20240327385-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | LIANG GUIBAI (US) | 2024-10-03 | — | — | US | disclosed |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054919-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-03-14 | — | — | WO | disclosed |
| EP-4324835-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2024-02-21 | — | — | EP | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| CN-114805389-B | Tricyclic dihydro-imidazo pyrimidinone derivatives, preparation method, pharmaceutical compositions and uses thereof | 上海赛默罗生物科技有限公司 | 2023-08-29 | — | — | CN | disclosed |
| EP-4223368-A1 | MACROCYCLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2023-08-09 | — | — | EP | disclosed |
| WO-2005028440-A1 | NOVEL GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-1129070-A4 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004009599-A1 | FIVE-MEMBERED HETEROAROMATIC OLEFINIC AZACYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE AS INHIBITORS OF NCOTINIC CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | TARGACEPT, INC. | 2002-10-31 | — | — | US | disclosed |
| EP-1129070-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-09-05 | — | — | EP | disclosed |
| US-6228872-B1 | PEPTIDE-PROLYL ISOMERASE AND ROTAMASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-08 | — | — | US | disclosed |
| WO-2000027811-A1 | NEUROTROPHIC DIAMIDE AND CARBAMATE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-18 | — | — | WO | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5409946-A | Antiepileptic agent | ABBOTT LABORATORIES (US) | 1995-04-25 | — | — | US | disclosed |
| CN-1022244-C | Tetrazole excitatory amino acid receptor antagonists | LILLY CO ELI (US) | 1993-09-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327385-A1 | SUBSTITUTED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | REN, ACE, AGTR1 | FKBP1A 3406/4885HSD17B10 1991/4885SMN1; SMN2 4097/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | FKBP1A 3515/4885HSD17B10 2991/4885SMN1; SMN2 4787/4885 |
| US-20240246995-A1 | PYRIMIDINONE DERIVATIVE AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | PLA2G1B, LYPLAL1, PLA2G12B | FKBP1A 2621/4885HSD17B10 1893/4885SMN1; SMN2 2755/4885 |
| US-20250092030-A1 | ENHANCERS OF PARTICULATE GUANYLYL CYCLASE RECEPTOR A | PDE2A, GUCY1A1, GCGR | FKBP1A 3177/4885HSD17B10 2112/4885SMN1; SMN2 1018/4885 |
| US-20020160998-A1 | Pharmaceutical compositions and methods for use | AADAC, CYP3A7, CYP3A5 | FKBP1A 1384/4885HSD17B10 483/4885SMN1; SMN2 4695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.